4.6 Article

Deep learning with diffusion basis spectrum imaging for classification of multiple sclerosis lesions

Journal

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
Volume 7, Issue 5, Pages 695-706

Publisher

WILEY
DOI: 10.1002/acn3.51037

Keywords

-

Funding

  1. National Institutes of Health (NIH) [P01 NS059560]

Ask authors/readers for more resources

Objective Multiple sclerosis (MS) lesions are heterogeneous with regard to inflammation, demyelination, axonal injury, and neuronal loss. We previously developed a diffusion basis spectrum imaging (DBSI) technique to better address MS lesion heterogeneity. We hypothesized that the profiles of multiple DBSI metrics can identify lesion-defining patterns. Here we test this hypothesis by combining a deep learning algorithm using deep neural network (DNN) with DBSI and other imaging methods. Methods Thirty-eight MS patients were scanned with diffusion-weighted imaging, magnetization transfer imaging, and standard conventional MRI sequences (cMRI). A total of 499 regions of interest were identified on standard MRI and labeled as persistent black holes (PBH), persistent gray holes (PGH), acute black holes (ABH), acute gray holes (AGH), nonblack or gray holes (NBH), and normal appearing white matter (NAWM). DBSI, diffusion tensor imaging (DTI), and magnetization transfer ratio (MTR) were applied to the 43,261 imaging voxels extracted from these ROIs. The optimized DNN with 10 fully connected hidden layers was trained using the imaging metrics of the lesion subtypes and NAWM. Results Concordance, sensitivity, specificity, and accuracy were determined for the different imaging methods. DBSI-DNN derived lesion classification achieved 93.4% overall concordance with predetermined lesion types, compared with 80.2% for DTI-DNN model, 78.3% for MTR-DNN model, and 74.2% for cMRI-DNN model. DBSI-DNN also produced the highest specificity, sensitivity, and accuracy. Conclusions DBSI-DNN improves the classification of different MS lesion subtypes, which could aid clinical decision making. The efficacy and efficiency of DBSI-DNN shows great promise for clinical applications in automatic MS lesion detection and classification.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica

John R. Ciotti, Noah S. Eby, Matthew R. Brier, Gregory F. Wu, Salim Chahin, Anne H. Cross, Robert T. Naismith

Summary: MOGAD patients exhibit fewer brain lesions and lower CVS positivity compared to MS patients. They also show longer involvement in the spinal cord and optic nerve. The optic nerve pathology in MOGAD tends to be bilateral/anterior with perineural contrast enhancement, contrasting with NMOSD.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal

Alan J. Thompson, William Carroll, Olga Ciccarelli, Giancarlo Comi, Anne Cross, Alexis Donnelly, Anthony Feinstein, Robert J. Fox, Anne Helme, Reinhard Hohlfeld, Robert Hyde, Pamela Kanellis, Douglas Landsman, Catherine Lubetzki, Ruth Ann Marrie, Julia Morahan, Xavier Montalban, Bruno Musch, Sarah Rawlings, Marco Salvetti, Finn Sellebjerg, Caroline Sincock, Kathryn E. Smith, Jon Strum, Paola Zaratin, Timothy Coetzee

Summary: This paper reviews recent progress in progressive multiple sclerosis (MS), highlighting the need for a deeper understanding of underlying mechanisms, identification of therapeutic targets, and improved clinical trial design. A global research strategy proposed by the International Progressive MS Alliance aims to address challenges and improve quality of life for MS patients.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Microstructural Periventricular White Matter Injury in Post-hemorrhagic Ventricular Dilatation

Albert M. Isaacs, Jeffrey J. Neil, James P. McAllister, Sonika Dahiya, Leandro Castaneyra-Ruiz, Harri Merisaari, Haley E. Botteron, Dimitrios Alexopoulous, Ajit George, Peng Sun, Diego M. Morales, Joshua Shimony, Jennifer Strahle, Yan Yan, Sheng-Kwei Song, David D. Limbrick, Christopher Smyser

Summary: This study used diffusion basis spectrum imaging (DBSI) to investigate the neurologic deficits of neonatal post-hemorrhagic hydrocephalus (PHH). The results showed that infants with PHH had severe white matter abnormalities and specific patterns of axonal and myelin injury, fiber loss, cellular infiltration, and inflammation. The study also found a correlation between increasing ventricular size and worse DBSI metrics.

NEUROLOGY (2022)

Editorial Material Clinical Neurology

Confirming a Historical Diagnosis of Multiple Sclerosis Challenges and Recommendations

Andrew J. Solomon, Georgina Arrambide, Wallace Brownlee, Anne H. Cross, Maria I. Gaitan, Fred D. Lublin, Naila Makhani, Ellen M. Mowry, Daniel S. Reich, Alex Rovira, Brian G. Weinshenker, Jeffrey A. Cohen

Summary: Patients with a historical diagnosis of multiple sclerosis (MS) face specific challenges in diagnosis and treatment. Retrospective application of the McDonald criteria can be difficult, complicating confirmation of an early MS diagnosis and assessment of disease progression.

NEUROLOGY-CLINICAL PRACTICE (2022)

Article Clinical Neurology

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

Stephen L. Hauser, Anne H. Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G. Meuth, Paul S. Giacomini, Francesco Sacca, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A. Haring, Valentine Jehl, Bernd C. Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi, Ludwig Kappos

Summary: Ofatumumab demonstrates good safety and tolerability in the treatment of RMS patients for up to 3.5 years, with no new safety risks identified, supporting its established effectiveness.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS

Biao Xiang, Matthew R. Brier, Manasa Kanthamneni, Jie Wen, Abraham Z. Snyder, Dmitriy A. Yablonskiy, Anne H. Cross

Summary: This study evaluated qGRE-derived R2t* as an imaging biomarker of progressive multiple sclerosis (MS) and found that reductions in R2t* were associated with neurological impairment. R2t* performed better than other imaging measures in assessing disease progression.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

Jutta Gaertner, Stephen L. Hauser, Amit Bar-Or, Xavier Montalban, Jeffrey A. Cohen, Anne H. Cross, Kumaran Deiva, Habib Ganjgahi, Dieter A. Haering, Bingbing Li, Ratnakar Pingili, Krishnan Ramanathan, Wendy Su, Roman Willi, Bernd Kieseier, Ludwig Kappos

Summary: The study showed that ofatumumab is more effective and safer than teriflunomide in recently diagnosed, treatment-naive patients with relapsing multiple sclerosis. Compared with teriflunomide, ofatumumab significantly reduced the annualized relapse rate, delayed confirmed disability worsening, and delayed progression independent of relapse activity.

MULTIPLE SCLEROSIS JOURNAL (2022)

Letter Clinical Neurology

COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes

Amber Salter, Anne H. Cross, Gary R. Cutter, Robert J. Fox, David K. B. Li, Bruce Bebo, June Halper, Pamela Kanellis, Kottil Rammohan, Scott D. Newsome

Summary: This study reports the COVID-19 outcomes of 36 women with multiple sclerosis (MS), including pregnant and postpartum women. A comparison between pregnant/postpartum females and non-pregnant/postpartum females showed no increased risks for women with MS in relation to COVID-19.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Article Clinical Neurology

Evaluating brain damage in multiple sclerosis with simultaneous multi-angular-relaxometry of tissue

Biao Xiang, Jie Wen, Robert E. Schmidt, Alexander L. Sukstanskii, Daniel Mamah, Dmitriy A. Yablonskiy, Anne H. Cross

Summary: This study developed an alternative approach, Simultaneous-Multi-Angular-Relaxometry-of-Tissue (SMART) MRI, to generate a quantitative magnetization transfer MRI metric called the macromolecule proton fraction (MPF) that correlates with myelin concentration. The SMART-derived MPF metric was tested as a potential imaging biomarker of demyelination and was found to differentiate different types of multiple sclerosis lesions and correlate with clinical test scores. The results suggest that SMART-derived MPF metric holds promise for quantitatively assessing demyelination and remyelination.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2022)

Article Neurosciences

Twelve Weeks of Intermittent Caloric Restriction Diet Mitigates Neuroinflammation in Midlife Individuals with Multiple Sclerosis: A Pilot Study with Implications for Prevention of Alzheimer's Disease

Farzaneh Rahmani, Laura Ghezzi, Valeria Tosti, Jingxia Liu, Sheng-Kwei Song, Anthony T. Wu, Jayashree Rajamanickam, Kathleen A. Obert, Tammie L. S. Benzinger, Bettina Mittendorfer, Laura Piccio, Cyrus A. Raji

Summary: This study aimed to investigate the effect of intermittent caloric restriction (iCR) on neuroimaging markers of multiple sclerosis (MS). The results showed that after 12 weeks of iCR, there were improvements in brain volume, cortical thickness, and reduction in neuroinflammation in midlife adults with MS. These pilot data suggest therapeutic effects of iCR in MS patients.

JOURNAL OF ALZHEIMERS DISEASE (2023)

Article Clinical Neurology

Quantitative MRI identifies lesional and non-lesional abnormalities in MOGAD

Matthew R. Brier, Biao Xiang, John R. Ciotti, Salim Chahin, Gregory F. Wu, Robert T. Naismith, Dmitriy Yablonskiy, Anne H. Cross

Summary: This study used qGRE MRI to examine the brains of MOGAD patients and compared them with MS patients matched for disability. The results showed that non-lesional tissues in MOGAD patients were less damaged compared to MS, which may explain the greater propensity for recovery in MOGAD.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Clinical Neurology

Brain age predicts disability accumulation in multiple sclerosis

Matthew R. Brier, Zhuocheng Li, Maria Ly, Helmet T. Karim, Leda Liang, Weixin Du, John E. McCarthy, Anne H. Cross, Tammie L. S. Benzinger, Robert T. Naismith, Salim Chahin

Summary: Brain age, quantified using machine learning applied to structural MRI, is a clinically relevant biomarker that correlates with and predicts increasing disability in patients with multiple sclerosis (MS).

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Clinical Neurology

Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor

Amit Bar-Or, Anne H. Cross, Anthony L. Cunningham, Yann Hyvert, Andrea Seitzinger, Hans Guehring, Elise E. Drouin, Nektaria Alexandri, Davorka Tomic, Xavier Montalban

Summary: A post hoc analysis showed that Evobrutinib, an investigational drug for patients with relapsing multiple sclerosis (RMS), has an impact on immune responses. The results suggest that the drug acts as an immunomodulator, inhibiting aberrant immune cell responses while maintaining responsiveness to foreign and recall antigens.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Medicine, General & Internal

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials

Amit Bar-Or, Gian-Andrea Thanei, Christopher Harp, Corrado Bernasconi, Ulrike Bonati, Anne H. Cross, Saloumeh Fischer, Laura Gaetano, Stephen L. Hauser, Robert Hendricks, Ludwig Kappos, Jens Kuhle, David Leppert, Fabian Model, Annette Sauter, Harold Koendgen, Xiaoming Jia, Ann E. Herman

Summary: Baseline NfL levels are associated with brain atrophy, lesion expansion, and clinical progression in MS patients. Ocrelizumab treatment reduces NfL levels and eliminates the predictive value of baseline NfL on disability progression. Elevated NfL levels following ocrelizumab treatment may predict increased risk for clinical progression.

EBIOMEDICINE (2023)

Article Clinical Neurology

Stronger Microstructural Damage Revealed in Multiple Sclerosis Lesions With Central Vein Sign by Quantitative Gradient Echo MRI

Victoria A. Levasseur, Biao Xiang, Amber Salter, Dmitriy A. Yablonskiy, Anne H. Cross

Summary: The study found that CVS occurred in similar proportions in different MS subtypes, and CVS-positive lesions exhibited greater tissue damage and larger size compared to CVS-negative lesions.

JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE (2022)

No Data Available